About The Lancet HIV
About the journal
The Lancet HIV launches in autumn 2014, joining the growing collection of Lancet specialty journals. As an exclusively online journal, this new monthly title will be dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. The journal offers the same unique Fast Track experience offered by The Lancet journals for all research papers selected for peer review, whereby articles can be published online within 8 weeks of submission.
About our content
Delivering a holistic view of the pandemic, The Lancet HIV publishes original research, comment, and correspondence that unifies clinical, epidemiological, and operational disciplines across a single vision of health for those living with HIV. The journal will cover innovative treatments and the biological research underpinning such developments, novel methods of service delivery, and new ways of confronting HIV/AIDS worldwide.
About the Editor
Peter Hayward was Deputy Editor of The Lancet Infectious Diseases from 2010 and helped to introduce original research and Fast Track peer review to that journal. He is the founding Editor of The Lancet HIV.
About the Editorial Advisory board
The Editorial Advisory Board will consists of key opinion leaders and researchers from around the world who lend their expertise to this journal. If you are interested in finding out more about participating as an Editorial Advisory Board Member, please emailTheLancetHIV@lancet.com.
The Lancet HIV投稿指南
The Lancet HIV is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. We will publish translational, epidemiological, clinical, operational, and implementation studies. All original research judged eligible for consideration by the journal’s editors will be peer-reviewed within 72 h and, if accepted, published online within 8 weeks from submission. The journal will also publish relevant commentary and correspondence. Wherever possible, figures and good quality photographs (colour or black and white) should be used to supplement and to enhance the text. We also welcome videos. Further details on the different sections of The Lancet HIV, and how to submit to the journal, are provided below. If you require further clarification, the journal's editorial staff will be pleased to help (email TheLancetHIV@lancet.com).
Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. The Lancet journals are signatories of the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations) and to the Committee on Publication Ethics (COPE) code of conduct for editors. We follow COPE's guidelines.
- Authors and contributors
- Declaration of interests
- Role of the funding source
- Role of medical writer or editor
- Patient and other consents
- Types of article and manuscript requirements
- Formatting guidelines
- Guidelines for supplementary material
- Disclosure of results before publication
- Online First publication
- How The Lancet HIV handles your paper
- Open access and funding
- What happens after publication?
Download a PDF version of the full guidelines for authors of The Lancet HIV.
The Lancet HIV投稿网址
The Lancet HIV投稿网址为ees.elsevier.com/thelancethiv/。
如果有不错的稿件，可以考虑投The Lancet HIV，虽然现在还没有影响因子，但是背靠The Lancet这颗大树，相信将来影响因子会少不了。而且现在杂志刚创刊，稿件可能有限，中稿率可能会高些。